Analysts have upgraded revenue forecasts for NewAmsterdam Ph...
Analysts have upgraded revenue forecasts for NewAmsterdam Pharma next year, despite slower expected growth than the industry. They also increased the price target, indicating an improved intrinsic business value.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3170Followers
0Following
7923Visitors
Follow